BioCentury
ARTICLE | Company News

Yabao gains Chinese rights to Lilly diabetes compound

July 7, 2014 11:41 PM UTC

Eli Lilly and Co. (NYSE:LLY) granted Yabao Pharmaceutical Group Co. Ltd. (Shanghai:600351) Chinese rights to develop and commercialize Lilly's diabetes compound LY2608204. The glucokinase ( GCK; GK) a...